首页 | 本学科首页   官方微博 | 高级检索  
     


Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer
Authors:Tanya B. Dorff MD  Jeff A. Longmate PhD  Sumanta K. Pal MD  Walter M. Stadler MD  Mayer N. Fishman MD  PhD  Ulka N. Vaishampayan MD  Amol Rao MD  Jacek K. Pinksi MD  PhD  James S. Hu MD  David I. Quinn MBBS  PhD  Primo N. Lara MD Jr
Affiliation:1. University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, California;2. Department of Biostatistics, City of Hope, Duarte, California;3. Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California;4. Hematology/Oncology Section, University of Chicago, Chicago, Illinois;5. Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;6. Department of Hematology and Oncology, Karmanos Cancer Center, Detroit, Michigan;7. Department of Medical Oncology, University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, California;8. University of California Davis Comprehensive Cancer Center, Sacramento, California
Abstract:
Keywords:angiogenesis  renal cancer  targeted therapy  transforming growth factor β   (TGFβ  )  vascular endothelial growth factor (VEGF)
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号